Metabolic and endocrine studies in women using norethindrone acetate implant.
Subcutaneously administered implant-D containing 40 mg of Norethindrone acetate in a single silastic implant was offered to 79 subjects who desired spacing of their family. The effect of constant release of steroid from this device on metabolic and endocrine functions was studied. Each subject in the pretreatment state served as her own control. The device was removed at 8 months initially and subsequently at 5-6 months. The clinical acceptability of this method was fairly high. The results reported in this study show that Norethindrone acetate administered in this way did not cause any adverse reactions on endocrine and metabolic functions as gauged by the parameters analysed.
D000328:Adult; D001774:Blood Chemical Analysis; D003271:Contraceptive Agents, Female / Q000494:pharmacology*; D004343:Drug Implants; D005260:Female; D006801:Humans; D008099:Liver / Q000378:metabolism; D008660:Metabolism / Q000187:drug effects*; D009640:Norethindrone / Q000494:pharmacology*
D003271:Contraceptive Agents, Female; D004343:Drug Implants; D009640:Norethindrone